Earlier this month, a report revealed that the United States had purchased 90% of the supply of remedicator, a drug effective in various research reports against the new corona virus, for the next three months.
Research reports have found that remedies help coronavirus patients recover faster.
The United States has purchased more than 500,000 of its courses by September.
The United States will receive 100 percent of Gilad's proposed production for July, while 90 percent of August and September production will go to the United States.
It has now been revealed that the US government has bought 100 million doses of the Code 19 vaccine, developed by Pfizer Inc. and the German company BioNTSE, for 1.95 billion.
The companies also announced that the US government would be allowed to purchase another 500 million doses.
The Trump administration plans to spend billions of dollars developing and purchasing effective vaccines to prevent code 19.
To this end, Operation RapeSpeed, a joint program of the HHS and the Department of Defense, has been launched to accelerate the process of vaccination, treatment and diagnosis against the corona virus.
About 250 corona virus vaccines are being developed worldwide, many of which have entered the human testing phase.
Premature doses are being purchased by various governments through agreements with vaccine companies.
The Phaser and Biotech vaccines are one of the few vaccines that are being tested in large trials and the results were encouraging in the early stages of human trials.
Pfizer will provide doses of the vaccine to the United States only after it has been approved for emergency use by the US Food and Drug Administration.
This permission will be granted when the vaccine is safe and effective in the third phase of the clinical trial.
Both companies say they will be ready to get some kind of regulatory approval by October when the ongoing research is successful.
These companies want to produce 100 million doses of the vaccine by the end of 2020, and by the end of 2021, that number will reach 1.3 billion.
The United States had earlier in May purchased 300 million doses of the experimental vaccine, developed by Oxford University in the United Kingdom.
The United States has promised to provide 2 1.2 billion to AstraZeneca, a vaccine company.
On the occasion, US Health Secretary Alex Azar said that the agreement with AstraZenka is a significant step forward for Operation Rapid Speed, which aims to ensure a safe, effective and widely available vaccine by 2021.
The first doses of the vaccine will be available in the United States in early October, according to the statement.
The United States has also entered into similar agreements with other vaccine companies, including Johnson & Johnson, Moderina and the French company Sanofi.
The head of Sanofi had angered the French government with his statement in May when he said that doses of the vaccine that would be prepared in the United States would be given to American patients first because the country had funded the research. Assistance provided.
Earlier in March, German officials made strong statements against the United States over the development of a vaccine.
At the time, Deutsche Welle reported that a German company, Cureweek, was working on a vaccine against the corona virus.
The report quoted sources as saying that US President Donald Trump had offered German scientists working on the vaccine a hefty compensation because they wanted to get their work rights.
The company expects the experimental vaccine to be ready by June or July and then allow people to test it, but it denied the report.
The company's co-founder told Reuters that several possible vaccines were being researched and that the best two would be selected for clinical trials.
Daniel Manichella, the former CEO of the German company, attended a meeting at the White House on March 2 to discuss the development of a vaccine against the corona virus.
But on March 11, the company replaced Daniel Manichella with founder Ingram Hoyer and gave no reason.
